UNICREDIT BANK/CALL/MODERNA/200/0.1/18.06.25 | Real-time BOERSE MUENCHEN 20:42:00 24/05/2024 BST | ||
| 2.72 EUR | +6.67% |
|
| Current month | +249.32% | ||
| 1 month | +280.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 2.72 | +6.67% |
| 23/05/24 | 2.55 | -1.92% |
| 22/05/24 | 2.6 | +65.61% |
| 21/05/24 | 1.57 | +6.80% |
| 20/05/24 | 1.47 | +22.50% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 08:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HC7U68 |
| ISIN | DE000HC7U680 |
| Date issued | 30/06/2023 |
| Strike | 200 $ |
| Maturity | 18/06/2025 (390 Days) |
| Parity | 10 : 1 |
| Emission price | 1.87 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.81 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.02 € |
| Spread % | 0.74% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
164
USD
Average target price
138.5
USD
Spread / Average Target
-15.55%
- Stock Market
- Warrants
- Warrant
